Bottom line
XBI vs IBB: the short answer
XBI (State Street(R) SPDR(R) S&P(R) Biotech ETF) and IBB (iShares Biotechnology ETF) are quite different portfolios: only about 4% of their top holdings (by weight) are shared.
XBI is cheaper at 0.35% vs 0.44% — a difference of $9.00 a year per $10,000 invested.
Over five years, IBB returned +2.5% a year vs −2.7% for XBI.
Updated Nov 19, 2026
XBI vs IBB side by side
| XBI | IBB | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | iShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 0.44% |
| Annual cost per $10k | $35 | $44 |
| 10-yr cost on $10k (prospectus) | $443 | $555 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +35.8% | +28.0% |
| 5-yr return (annualized) | −2.7% | +2.5% |
| 10-yr return (annualized) | +5.8% | +4.4% |
| Best quarter | +44.4% | +26.8% |
| Worst quarter | −26.2% | −22.9% |
| Net assets (fund) | $10.7B | $5.9B |
| Number of holdings | 161 | 254 |
| Portfolio turnover | 71% | 27% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XBI | IBB | Difference |
|---|---|---|---|
| 2025 | +35.8% | +28.0% | +7.8% |
| 2024 | +1.1% | −2.4% | +3.5% |
| 2023 | +7.5% | +3.6% | +3.9% |
| 2022 | −25.8% | −13.6% | −12.2% |
| 2021 | −20.5% | +1.0% | −21.5% |
| 2020 | +48.2% | +25.9% | +22.3% |
| 2019 | +32.2% | +24.8% | +7.5% |
| 2018 | −14.9% | −9.1% | −5.8% |
| 2017 | +43.7% | +21.2% | +22.5% |
| 2016 | −15.4% | −21.5% | +6.1% |
Source: Fund prospectus bar charts
Holdings overlap
2 of XBI's top 25 holdings also appear in IBB's top 25.
| Holding | XBI | IBB |
|---|---|---|
| Moderna Inc | 1.41% | 0.88% |
| Natera Inc | 1.16% | 2.11% |
Source: SEC Form N-PORT
XBI top 10
- State Street Global Advisors — 5.87%
- Apogee Therapeutics Inc — 1.49%
- Moderna Inc — 1.41%
- Twist Bioscience Corp — 1.41%
- Oruka Therapeutics Inc — 1.38%
- Kymera Therapeutics Inc — 1.36%
- Viking Therapeutics Inc — 1.30%
- Praxis Precision Medicines Inc — 1.29%
- Erasca Inc — 1.27%
- Revolution Medicines Inc — 1.20%
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FAQ
What is the difference between XBI and IBB?
Which is cheaper, XBI or IBB?
Should I own both XBI and IBB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.